Musk's X sues New York over requirement to show how social media platforms handle problematic posts
NEW YORK (AP) — Elon Musk 's X sued Tuesday to try to stop New York from requiring reports on how social media platforms handle problematic posts — a regulatory approach that the company successfully challenged in California.
New York's law, which Democratic Gov. Kathy Hochul signed late last year, is poised to take effect later this year. X maintains that the measure impinges on free speech rights and on a 1996 federal law that, among other things, lets internet platforms moderate posts as they see fit.
New York is improperly trying 'to inject itself into the content-moderation editorial process' by requiring 'politically charged disclosures' about it, Bastrop, Texas-based X Corp. argues in the suit.
'The state is impermissibly trying to generate public controversy about content moderation in a way that will pressure social media companies, such as X Corp., to restrict, limit, disfavor or censor certain constitutionally protected content on X that the state dislikes,' says the suit, filed in federal court in Manhattan.
New York Attorney General Letitia James' office didn't immediately respond to a request for comment on the case.
The law requires social media companies to report twice a year on whether and how they define hate speech, racist or extremist content, disinformation and some other terms. The platforms also have to detail their content moderation practices and data on the number of posts they flagged, the actions they took, the extent to which the offending material was seen or shared, and more.
Sponsors Sen. Brad Hoylman-Sigal and Assembly Member Grace Lee, both Democrats, have said the measure will make social media more transparent and companies more accountable.
The law applies broadly to social media companies. But X is among those that have faced intense scrutiny in recent years, and in a 2024 letter to an X lobbyist, the sponsors said the company and Musk in particular have a 'disturbing record' that 'threatens the foundations of our democracy.'
The lawmakers wrote before Musk became, for a time, a close adviser and chainsaw-wielding cost-cutter in Republican President Donald Trump's administration. The two billionaires have since feuded and, perhaps, made up.
Since taking over the former Twitter in 2022, Musk, in the name of free speech, has dismantled the company's Trust and Safety advisory group and stopped enforcing content moderation and hate speech rules that the site followed. He has restored the accounts of conspiracy theorists and incentivized engagement on the platform with payouts and content partnerships.
Outside groups have since documented a rise in hate speech and harassment on the platform. X sued a research organization that studies online hate speech – that lawsuit was dismissed last March.
The New York legislation took a page from a similar law that passed in California — and drew a similar lawsuit from X.
Last fall, a panel of federal appellate judges blocked portions of the California law, at least temporarily, on free speech grounds. The state subsequently settled, agreeing not to enforce the content-moderation reporting requirements.
___
AP Technology Writer Barbara Ortutay contributed from San Francisco.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
Acurx Pharmaceuticals, Inc. Announces Exercise of Warrants for $2.67 Million Gross Proceeds
STATEN ISLAND, N.Y., June 17, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced that it has entered into a warrant inducement agreement (the "Letter Agreement") with a certain holder ("Holder") of existing warrants to purchase up to an aggregate of 4,445,435 shares of common stock (the "Existing Warrants") having exercise prices ranging from $3.25 to $3.26 per share, issued by the Company in July 2022 and May 2023, wherein the Holder agreed to exercise the Existing Warrants at a reduced exercise price of $0.675 per share, resulting in gross proceeds of approximately $2.67 million, before deducting offering fees and other expenses payable by the Company. In consideration for the exercise of the Existing Warrants for cash, the investors received 6,223,609 G-1 warrants (the "G-1 Warrants") and 2,667,261 G-2 warrants (the "G-2 Warrants) to purchase up to an aggregate of 8,890,870 shares of common stock (the "New Warrants"). The G-1 Warrants are exercisable immediately at an exercise price of $0.425 per common share and will expire five years from the issuance date. The G-2 Warrants are exercisable upon shareholder approval at an exercise price of $0.425 per common share and will expire five years from the issuance date. The shares of common stock issuable upon exercise of the Existing Warrants are registered pursuant to effective resale registration statements on Form S-1 (File Nos. 333-267412 and 333-273015). The transaction is expected to close no later than June 20, 2025, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the exercise for working capital and general corporate purposes. The New Warrants are being issued in a private placement pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"), and Regulation D promulgated thereunder and, along with the shares of common stock underlying such New Warrants, have not been registered under the Securities Act, or applicable state securities laws. Accordingly, the New Warrants and underlying shares of common stock may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About Ibezapolstat Ibezapolstat is the Company's lead antibiotic candidate advancing to international Phase 3 clinical trials to treat patients with C. difficile Infection (CDI). Ibezapolstat is a novel, orally administered antibiotic being developed as a Gram-Positive Selective Spectrum (GPSS®) antibacterial. It is the first of a new class of DNA polymerase IIIC inhibitors under development by Acurx to treat bacterial infections. Ibezapolstat's unique spectrum of activity, which includes C. difficile but spares other Firmicutes and the important Actinobacteria phyla, appears to contribute to the maintenance of a healthy gut microbiome. In June 2018, ibezapolstat was designated by the U.S. Food and Drug Administration (FDA) as a Qualified Infectious Disease Product (QIDP) for the treatment of patients with CDI and will be eligible to benefit from the incentives for the development of new antibiotics established under the Generating New Antibiotic Incentives Now (GAIN) Act. In January 2019, FDA granted "Fast Track" designation to ibezapolstat for the treatment of patients with CDI. The CDC has designated C. difficile as an urgent threat highlighting the need for new antibiotics to treat CDI. About Acurx Pharmaceuticals, Inc. Acurx Pharmaceuticals is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. The Company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS®) that blocks the active site of the Gram+ specific bacterial enzyme DNA polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its R&D pipeline includes antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile, methicillinresistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE) and drug-resistant Streptococcus pneumoniae (DRSP). To learn more about Acurx Pharmaceuticals and its product pipeline, please visit Forward-Looking Statements Any statements in this press release about our future expectations, plans and prospects, including statements regarding our strategy, future operations, prospects, plans and objectives, the timing and completion of the offering; the satisfaction of customary closing conditions related to the offering and the intended use of proceeds therefrom, and other statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: whether ibezapolstat will benefit from the QIDP designation; whether ibezapolstat will advance through the clinical trial process on a timely basis; whether the results of the clinical trials of ibezapolstat will warrant the submission of applications for marketing approval, and if so, whether ibezapolstat will receive approval from the FDA or equivalent foreign regulatory agencies where approval is sought; whether, if ibezapolstat obtains approval, it will be successfully distributed and marketed; and other risks and uncertainties described in the Company's annual report filed with the Securities and Exchange Commission on Form 10-K for the year ended December 31, 2024, and in the Company's subsequent filings with the Securities and Exchange Commission. Such forward- looking statements speak only as of the date of this press release, and Acurx disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances after the date of such statements, except as may be required by law. Investor Contact: Acurx Pharmaceuticals, Inc. David P. Luci, President & Chief Executive Officer Tel: 917-533-1469 Email: davidluci@ View original content: SOURCE Acurx Pharmaceuticals, Inc. Sign in to access your portfolio
New York Times
18 minutes ago
- New York Times
On his first day with the Giants, Rafael Devers finds a whole new reality
One meeting, that's all it took. One meeting with his new San Francisco Giants superiors, and suddenly Rafael Devers no longer was Rafael Diva. Funny how that works when bosses communicate their wishes, and do not simply assume a player with a $313.5 million contract should do whatever they want. People skills. They might be baseball's new market inefficiency. Advertisement The Boston Red Sox never shared their intentions with Devers when they were trying to sign free-agent third baseman Alex Bregman, prompting Devers to initially balk at becoming a DH and then outright refuse to move to first base. The Giants related to Devers that only four teams entered Tuesday with a worse OPS at first base, or something to that effect. And voila! There was Devers, all smiles at his introductory news conference, saying, 'I am here to play wherever they want me to play.' Including first base, where he took grounders before his Giants debut. 'I don't think it's going to be too difficult for him,' Giants manager Bob Melvin said. 'More than anything, the fact he hasn't played in the field this year, we have to take our time working him in. It's a new position. We'll take it day to day.' Devers is not above reproach for refusing to do the same for the Red Sox, no matter how much he believes they slighted him. But here's rooting for this trade to work out for Giants president of baseball operations Buster Posey, and not simply because he appears to have a better feel for players than Red Sox chief baseball officer Craig Breslow. Or even his predecessor, Farhan Zaidi, who made the same mistake with Brandon Crawford that Breslow did with Devers, failing to inform his incumbent shortstop that he was agreeing to terms with another, Carlos Correa. This deal is a referendum on teams that define players more as 'dudes' – Posey's word – than 'assets.' A referendum on all the other fancy terms executives use, from flexibility to sustainability to efficiency, while hedging their bets and operating out of fear. A referendum on absorbing contracts that might not age well to do what every team should be trying to do – win. Devers' remaining $255 million or so over the next eight-plus years isn't as onerous as it might appear. Not when accounting for the approximately $32 million the Giants offloaded in the deal by including right-hander Jordan Hicks. And not when Vladimir Guerrero just signed a 14-year, $500 million extension that will begin next season when he is 27, one year younger than Devers is now. Guerrero's career OPS+ is 136. Devers' is 129. Advertisement Yet, the opinion of a number of rival executives, as related by The Athletic's Britt Ghiroli, is that the Red Sox all but pulled a fast one on the Giants. 'Freeing up $250 million AND getting some nice young talent in return is a great deal for them in a vacuum,' one exec said. 'In a few years I think this trade will be lauded,' another opined. Perhaps that is true. Perhaps Devers' questionable conditioning and lack of athleticism will cause him to decline faster than most. Perhaps two of the four players the Red Sox acquired, left-hander Kyle Harrison and 2024 first rounder James Tibbs III, will develop into a quality starting pitcher and productive outfielder, respectively. But once upon a time, before teams became obsessed with projections and modeling, the most effective way to evaluate a trade was by asking the question: Who got the best player in the deal? Without question, the best player in this deal is Devers, for this season and likely several beyond. And all those in the industry questioning Posey's bold move need to acknowledge that the Giants are operating in unique circumstances, not a vacuum. The Giants in recent years repeatedly were rejected by top sluggers, from Giancarlo Stanton to Bryce Harper, Aaron Judge to Shohei Ohtani. Citing medical concerns, they backed out of a deal on a player who was willing to come, Correa. Devers, lacking a no-trade clause (oops!), could not reject them. So paying a premium for him, if that's what it even was, made more sense for the Giants than it did for other clubs. Obviously, not all teams are willing or able to make the same type of commitments as the Giants, who within the last 10 months also retained third baseman Matt Chapman for $151 million and signed free-agent shortstop Willy Adames for $182 million. And let's not ignore reality. Posey, who became president of baseball operations last September, likely will learn the same hard lessons that scar many of his peers: Big deals often do not work out. Advertisement Yet, too often in this sport, teams in markets large and small hedge their bets, playing for tomorrow. Posey, who helped the Giants win three World Series as a player, is having none of it. In an interview earlier this month with the San Francisco Standard's Tim Kawakami, Posey all but signaled his approach to trading season, saying he 'loved' the Giants' 2011 acquisition of outfielder Carlos Beltrán, a rental, for right-hander Zack Wheeler, then a top 100 prospect. The move didn't work out. The Giants failed to make the playoffs that season. Wheeler, after overcoming a series of injuries, including Tommy John surgery, became one of the top pitchers in the game. But Posey, then the Giants' catcher, appreciated, 'the leader of our operation saying, 'Believe in you guys.'' The acquisition of Devers sends the same message, addressing the biggest need of a team that entered Tuesday third in the majors in ERA but only 14th in runs per game. Breslow, of course, believes in his team, too, as he made clear in his own news conference Monday. He indicated he would be active at the deadline, trying to replace some of the offense he lost with Devers. But of course, he never should have lost Devers in the first place. Breslow took responsibility for the breakdown in communication with his biggest star, saying, 'I absolutely need to have the humility to think back on the interactions and figure out what I could have done better.' But he also said the outcome might not have turned out differently, and portrayed Devers as a potentially negative influence on the team's young players. 'As we think about the identity, culture and environment that is created by great teams, there was something amiss here,' Breslow said. 'It was something we needed to act decisively to course-correct.' Well, the Red Sox's pattern of messy divorces with star players also is a threat to their identity, culture and environment, one that should give Roman Anthony and Co. pause when the team comes calling with extensions. Advertisement Breslow, like Posey, is a former player, a pitcher who spent 12 seasons in the majors from 2005 to '17. But while Posey draws praise from Giants players for his presence and leadership, Breslow is perceived by many inside and outside the Red Sox organization as remote, almost robotic. 'Alignment' – that was the fancy word Breslow and Red Sox CEO Sam Kennedy kept using Monday to describe what was missing with Devers. Posey spoke in much plainer terms Tuesday when describing Devers as a 'dude' and saying the qualities of such a player 'are not something you can quantify.' Introductory news conferences are always cause for celebration, and carry only so much weight. But the difference in Devers, who often shunned the media during his final months in Boston, was unmistakable. He laughed. He joked. He referenced Giants legend Barry Bonds sitting in the front row and cracked, 'Just looking at him, my game has improved a lot.' Funny how quickly the Giants turned Rafael Diva into Rafael Devers again. (Top photo of Rafael Devers: Thearon W. Henderson/Getty Images)
Yahoo
22 minutes ago
- Yahoo
US Fed set to hold rates steady as it guards against inflation
The US central bank is expected to hold interest rates steady Wednesday after its key policy meeting, as officials gauge the impact of tariffs on inflation -- and despite President Donald Trump's calls for rate cuts. The Federal Reserve has kept the benchmark lending rate unchanged this year at a range between 4.25 percent and 4.50 percent, and analysts expect policymakers will remain on the sidelines until price increases cool sustainably. While Trump has imposed a 10 percent tariff on most US trading partners and steeper levies on imports of steel, aluminum and autos in recent months, these have not triggered a price surge so far. This is partly because Trump has backed off or postponed some of his most punishing salvos, while businesses in turn have relied on existing inventory to avoid hiking consumer costs immediately. In May, the consumer price index edged up to 2.4 percent on-year from 2.3 percent in April, underscoring the limited effect of levies for now. But economists expect it will take several months for tariffs to flow into consumer prices, and the Fed is proceeding cautiously with interest rate adjustments. "The Fed would no doubt be cutting again by now if not for the uncertainty regarding tariffs and a recent escalation of tensions in the Middle East," said KPMG senior economist Benjamin Shoesmith. The prospect of higher inflation will probably keep the central bank in "wait-and-see mode for much of this year," he added in a note. Officials will want to see "if those factors trigger more than a transitory increase in prices," he said. Beyond inflation data, policymakers are also trying to keep expectations "anchored," a state in which consumers expect price increases to remain low and steady. If there are widespread expectations of price hikes, inflation could rise as businesses increase customer costs and workers seek higher wages. On Wednesday, the Fed is also due to release its latest economic projections on growth, unemployment and inflation. Analysts will monitor if the Fed still expects to make two more rate cuts this year as well. - 'Saber-rattling' - For his part, Trump has repeatedly urged the independent central bank to slash rates, calling Fed Chair Jerome Powell "too late" in doing so and "a fool" for holding off further cuts at the bank's May meeting. Trump has pointed to benign US inflation in arguing for interest rate cuts. More recently, he also cast such a move as a way for the country to "pay much less interest on debt coming due," overlooking the fact that lower interest rates usually raise consumer prices. Powell however has maintained that the Fed's rate-setting committee would make its decisions based solely on objective and non-political analysis, the Fed previously said. The Fed chair has also defended US central bank independence over rates in his recent meeting with Trump. Despite Trump's pressure, Allianz Trade North America senior economist Dan North expects Powell will not be too shaken by "saber-rattling." "Consumers are still spending, labor markets still creating jobs, although it is in fact slowing a little bit," North told AFP. "Certainly, the health of the economy doesn't beg for the Fed to cut rates," he added. "So we think they're on hold till the end of the year." myl-bys/dw Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
